We break viruses
This company is not in the game right now, so it has no score sheet.
Points come from real numbers anyone can check: new job posts, site traffic, software downloads and confirmed news. How scoring works
Facts from Y Combinator’s public list, last updated Nov 15. A free game. No real money. Points are a game score, not a judgment of what a company is worth.
Something wrong, or want this page gone? Fix or remove this page. Removal requests from a company's team are always honored. Founder of Pardes Biosciences? Claim this page for a Founder-verified badge and your own pitch.
Pardes develops pill-form antivirals that block viruses from copying themselves inside the body, aimed at drugmakers and patients.
Think of it as a small, early-stage Pfizer antiviral lab focused on respiratory viruses.
Few antiviral drugs exist for many viruses, so when a new outbreak hits, patients wait years for treatment. Developing a drug is slow and very expensive, which keeps smaller teams out.
Chemists design small molecules that fit into a key enzyme a virus needs to multiply, jamming it so the virus cannot make copies of itself. The result is a pill a patient can take by mouth.
Drug companies and governments usually pay through licensing or partnership deals with milestone payments, and patients pay for approved pills through insurance or pharmacies.
Antiviral drug development is a large category dominated by big drugmakers with decades of experience. Pardes is a very early team in this crowded field, so it sits on the research and development side rather than selling a product today.
Why now: COVID showed governments and investors that fast antiviral pills matter, and better computer-aided drug design has made it cheaper to search for new candidates.
Written by AI from the company's public site. Not checked by the company. Something wrong? Fix it.